When combined with the results of the previous phase II study, these findings provide a rationale to continue investigating SNG001, not only in hospitalised patients with COVID-19 (in the context of ongoing virus evolution and likely emergence of new variants), but also more widely in patients with severe seasonal viral lung infections, due to the broad spectrum and variant agnostic antiviral activity of IFN-β. Here, IFNB1 is linked to COVID-19.